ISBN-13: 9783848481354 / Angielski / Miękka / 2012 / 240 str.
Sigma ( ) receptors are well established as an indipendent receptor family with its characteristic binding profile and distribution in the central nervous system. Activation of 1 receptors alters several neurotransmitter systems, in particular the dopamine (DA) neurotrasmission; however the exact role of 1 receptor in dopaminergic homeostasis remains unclear. The DA transporter (DAT) is the primary mechanism by wich dopaminergic neurons terminate the signal, thus regulating the temporal aspects of dopaminergic synaptic transmission. This study shows for the first time that, in cell models, 1 receptors directly modulate the DAT activity. Facilitation of DA uptake induced by (+)-pentazocine, a powerful 1 agonist, is reflected on the increased cell susceptibility to DA toxicity; these effects are prevented by 1 selective antagonists. Since numerous compounds, including several drugs of abuse, activate 1 receptors, thus eliciting a severe dopaminergic neurons damage, the reported protective effect showed by 1 antagonists would indicate a novel pharmacological strategy to approach the dopaminergic neurodegenerative diseases (i.e. Parkinson's Disease) therapeutical management."
Sigma (σ) receptors are well established as an indipendent receptor family with its characteristic binding profile and distribution in the central nervous system. Activation of σ1 receptors alters several neurotransmitter systems, in particular the dopamine (DA) neurotrasmission; however the exact role of σ1 receptor in dopaminergic homeostasis remains unclear. The DA transporter (DAT) is the primary mechanism by wich dopaminergic neurons terminate the signal, thus regulating the temporal aspects of dopaminergic synaptic transmission. This study shows for the first time that, in cell models, σ1 receptors directly modulate the DAT activity. Facilitation of DA uptake induced by (+)-pentazocine, a powerful σ1 agonist, is reflected on the increased cell susceptibility to DA toxicity; these effects are prevented by σ1 selective antagonists. Since numerous compounds, including several drugs of abuse, activate σ1 receptors, thus eliciting a severe dopaminergic neurons damage, the reported protective effect showed by σ1 antagonists would indicate a novel pharmacological strategy to approach the dopaminergic neurodegenerative diseases (i.e. Parkinsons Disease) therapeutical management.